Investor Home

Investor Home

Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

Lefamulin

Nabriva’s lead pleuromutilin product candidate, lefamulin, is being studied in two global, registrational Phase 3 clinical trials for the treatment of moderate to severe ... More >>

Recent Newsmore >
12/20/16
Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia
-Blinded interim analysis to confirm sample size expected in February 2017 VIENNA, Austria and KING OF PRUSSIA, Pa., Dec. 20, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it has achieved 60% of its enrollment target in the lefamulin evaluation against pneumo... 
12/19/16
Nabriva Announces Closing of Rights Offering and Underwritten Offering
VIENNA, Austria and KING OF PRUSSIA, Pa., Dec. 19, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:NBRV) – Nabriva Therapeutics AG announced today the closing of its previously announced rights offering for up to 588,127 common shares, including common shares represented by American Depositary Shares (ADSs), to its existing common shareholders and ADS holders and its previously announced underwritten offering of 3,267,750 ADSs, representing all of the 326,775 unsubscribed common shares, including common shar... 
12/14/16
Nabriva Announces Results of Rights Offering and Pricing of Underwritten Offering
VIENNA, Austria and KING OF PRUSSIA, Pa., Dec. 14, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:NBRV) – Nabriva Therapeutics AG announced today the completion of its previously announced rights offering for up to 588,127 common shares, including common shares represented by American Depositary Shares (ADSs), to its existing common shareholders and ADS holders and an underwritten offering of 3,267,750 ADSs, representing all of the 326,775 unsubscribed common shares.  All of the ADSs and common shares ... 
Upcoming Eventsmore >
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.